Clinical Trial

Glutamatergic Modulation as a Treatment for Depressive Symptoms Among Patients With Post-acute Sequelae of COVID (PASC): A Pilot Trial

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 16, 2024 (before its estimated June 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
Post-acute sequelae of SARS-CoV2 (PASC), colloquially known as "long-COVID," is thought to affect between 10-30% of all COVID-19 survivors. Patients with PASC also report worsening behavioral health symptoms over time that include new-onset depression, anxiety, and even suicidal behavior. The purpose of this randomized, double-blind, controlled trial is to test the efficacy of a glutamate modulator among PASC patients suffering from new-onset or worsening of depressive symptoms.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2023-01-17; most recent amendment 2026-04-30.
Status change: Active, Not Recruiting → Terminated 2026-04-30
Status change: Recruiting → Active, Not Recruiting 2024-07-12
Status change: Not Yet Recruiting → Recruiting 2023-03-30
Trial Details
NCT Number NCT05690503
Lead Sponsor New York State Psychiatric Institute
Conditions Post-acute Sequelae of COVID-19, Depressive Symptoms, Cognitive Dysfunction
Enrollment 12 participants
Start Date 2023-03-20
Primary Completion 2025-06-30 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-07-16